Norway’s Lytix Biopharmahas come out of stealth mode and landed its first commercial deal by licensing lead asset LTX-315 to US-based Verrica Pharmaceuticals, Inc., which will now develop and commercialize it for dermatologic oncology indications.
Lytix hopes successful development will allow the compound’s use in other oncology indications, its management told Scrip.








